News

Basilea Pharma claims that BAL30072 has broad antimicrobial activity against multidrug-resistant Gram-negative ‘superbugs’ that are increasingly associated with potentially life- threatening infections in hospitals around the world. Additionally,

Evotec will provide drug discovery expertise covering in-vitro biology, medicinal chemistry and in-vitro and in-vivo pharmacology. As part of the collaboration, Evotec will apply their integrated drug discovery

Profil Institute for Clinical Research Cardiometabolic Research director Robert Schott said that assessing cardiac safety is a critical early objective for the evaluation of new drugs, particularly in

Flutiform HFA-MDI is said to be a fixed-dose combination of fluticasone and formoterol in a metered dose inhaler (MDI). SkyePharma said that the two Phase III trials will

Tekmira Pharma said that the EPO has granted claims (European patent no 1 519 714 B1) covering Tekmira’s proprietary manufacturing process and apparatus for the production of lipid

The FDA will review the protocol under its Special Protocol Assessment (SPA) program, under which it will give approval for the trial’s design, clinical endpoints and statistical analysis.

Grifols said that approval from the US Food and Drug Administration (FDA) for Flebogamma 10% DIF was obtained in July 2010 and final approval in Europe is expected

With the manufacturing license granted, Hebei Aoxing API Pharmaceucitcal Company submitted business license application, to manufacture Naloxone Hydrochloride API product, to the China Administrative Bureau of Industry and

Cymbalta is marketed by Eli Lilly and Company. Cymbalta is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder, generalised anxiety disorder, diabetic